CRN2M, UMR 6231, CNRS, Department of Neuroendocrinology-Neuroimmunology, Institut Fédératif Jean-Roche, Faculté de Médecine Secteur Nord, Université de Méditerranée, Marseille, France.
J Neuroendocrinol. 2009 Nov;21(11):869-77. doi: 10.1111/j.1365-2826.2009.01910.x. Epub 2009 Sep 1.
Despite extensive research on sporadic pituitary adenomas, it is not yet possible to assign one protein alteration to one specific type of pituitary adenomas. Nevertheless, alterations of the cAMP pathway appear to be molecular hallmarks of most growth hormone (GH)-secreting adenomas. However, these alterations do not confer specific phenotypes to patients carrying these alterations. In this review, we summarise the literature regarding signalling alterations observed in GH-secreting adenomas. We focus on Gsalpha alterations and their possible cross-talk with the extracellular signal-related kinase (ERK)1/2 pathway. In the light of results obtained on human somatotroph adenoma cells in primary culture and on models of murine somatotroph cell lines, we postulate a crucial role for ERK1/2 in GH-secreting adenomas downstream of cAMP pathway alterations that might impact the tumoural phenotype.
尽管对散发性垂体腺瘤进行了广泛的研究,但目前还不可能将一种蛋白质改变与一种特定类型的垂体腺瘤联系起来。然而,cAMP 途径的改变似乎是大多数生长激素(GH)分泌腺瘤的分子标志。然而,这些改变并不能赋予携带这些改变的患者特定的表型。在这篇综述中,我们总结了关于 GH 分泌腺瘤中观察到的信号改变的文献。我们重点介绍 Gsalpha 的改变及其与细胞外信号相关激酶(ERK1/2)途径的可能相互作用。根据在原代培养的人类生长激素腺瘤细胞和鼠类生长激素细胞瘤系模型上获得的结果,我们推测 ERK1/2 在 cAMP 途径改变下游的 GH 分泌腺瘤中发挥关键作用,这可能影响肿瘤表型。